menu
    • menu
    [{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma & Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Deudomperidone

    Menu

    Deudomperidone

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : CinRx Pharma

                            Deal Size : $59.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            CinDome Pharma Announces $40 Million Series B Extension

                            Details : The financing aims to support the continued development of CIN-102 (deudomperidone) for the treatment of chronic gastroparesis, including preparation for registrational trials.

                            Brand Name : CIN-102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : CinRx Pharma

                            Deal Size : $59.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : CinRx Pharma & Perceptive Advisors

                            Deal Size : $19.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for th...

                            Details : The net proceeds will be used to develop CinDome Pharma’s Phase 2 envision3D study of CIN-102 (deudomperidone), a new chemical entity based upon deuteration and novel formulation of domperidone in patients with diabetic gastroparesis.

                            Brand Name : CIN-102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 27, 2023

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : CinRx Pharma & Perceptive Advisors

                            Deal Size : $19.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            CinRx Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for th...

                            Details : CIN-102 (deudomperidone) is a new chemical entity based upon deuteration and novel formulation of domperidone (DA2-receptor antagonist), a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States.

                            Brand Name : CIN-102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 27, 2023

                            Lead Product(s) : Deudomperidone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth